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ABSTRACT
Cardiovascular complications are the leading cause of diabetes-related morbidity 
and mortality. Calpain, a calcium-dependent protease, is increased in diabetic hearts yet 
its role in diabetic heart disease has not been demonstrated. We hypothesized that 
inhibition of calpain activity via calpastatin (CAST) over-expression will reduce the 
onset of myocardial fibrosis, a hallmark of diabetic cardiomyopathy, in the Type 2 
murine model, db/db. Histological analysis together with gene expression measurements 
showed calpastatin over-expression reduced collagen content in db/db-CAST hearts. In 
order to understand the mechanisms responsible for this change, fibroblasts and known 
mediators of collagen synthesis and degradation were studied. Results indicated that 
calpain-induced derangements in MMP activity, stimulation of immune cells and up- 
regulation of cytokines responsible for promoting fibroblast differentiation and 
proliferation were reversed by calpastatin over-expression. This study shows that calpain 
inhibition is an effective means of decreasing collagen accumulation in the diabetic heart.
Keywords: diabetic cardiomyopathy; myocardial fibrosis; collagen; calpain; calpastatin; 
calpastatin over-expression, fibroblasts; db/db
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CHAPTER 1: INTRODUCTION
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Section 1.1: Diabetes Mellitus and its Associated Complications
Diabetes is a chronic, metabolic disorder; the body cannot produce insulin to 
regulate glucose or fails to use insulin adequately [1]. The result is elevated blood 
glucose levels which impair physiological functions and lead to damaged organs, nerves 
and vessels [1]. There are three main types of diabetes including gestational diabetes 
which occurs early in pregnancy but subsides after delivery [1-4],
Type 1 diabetes is an autoimmune disorder [1-4]. The body’s own T-cells attack 
the (3-cells for unknown reason thus destroying pancreatic endocrine function and causing 
absolute insulin deficiency [5]. Type 1 diabetes affects nearly 10% of the diabetic 
population and is usually diagnosed in children and young adults [2-4],
Type 2 diabetes is of multifactorial etiology. It is caused by the combined 
influence of genetic susceptibility and environmental variables such as age, weight, diet 
and physical inactivity [1,4-5]. Insulin production may not be sufficient to meet the 
body’s needs. Alternatively, insulin-resistance can develop where the pancreas continues 
to produce insulin but the body no longer responds to its action [5].
Diabetes is a global pandemic; by 2030, nearly 400 million people will have been 
diagnosed with it [3]. In Canada alone, 1.2 million people are expected to be diagnosed 
between 2010 and 2020, bringing the total to 3.7 million [2]. Coping with diabetes is a 
tremendous struggle in itself. Nonetheless, it can introduce a number of complications 
including visual impairments and blindness, nerve and kidney damage [1-4]. However, 
the greatest challenges lie in cardiovascular complications, now the leading cause of 
diabetes-related morbidity and mortality [3-4], In Canada, 80% of diabetics die from a
heart attack or a stroke [2]. In 2004 in the United States, heart disease was noted on 68% 
of diabetes-related death certificates among people aged 65 years or older [1].
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Section 1.2: Cardiovascular complications and glycaemic control
Hyperglycaemia may be a risk factor for the development and progression of 
cardiovascular disease similar to total cholesterol and blood pressure [6].
Epidemiological studies have long indicated a clear connection between the level of 
hyperglycaemia and the occurrence of cardiovascular disease [7-11]. Surprisingly, 
glycaemia does not need to rise to diabetic levels to increase the risk of cardiovascular 
complications as even slight, sustained elevations in blood sugar are sufficient [8, 9, 11, 
12].
In the Framingham Study, diabetic men had more than twice the frequency of 
heart failure than their non-diabetic counterparts [7, 9,13-15]. Diabetic women are also 
five times more susceptible to heart failure [7, 9, 13-15]. Additionally, diabetes can also 
have a detrimental effect on the outcome of cardiovascular disease. Studies suggest that 
following myocardial infarction, diabetic hearts are more likely to fail through future 
cardiac events [7].
Clinical trials such as the Diabetes Control and Complications Trial (DCCT) and 
the United Kingdom Prospective Diabetes Study (UKPDS) involving patients with Types 
1 and 2 diabetes, respectively, have conclusively shown reductions in the risks of 
diabetes complications after intensive diabetes therapy (IDT) [6, 8, 16]. Unlike 
conventional therapy which aims only to prevent the symptoms of hyperglycaemia and 
hypoglycaemia, IDT involved a more stringent regimen of insulin treatment [16].
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Intensive control of blood glucose reduced the risk of cardiovascular events by 42% and 
severe clinical events, defined as non-fatal myocardial infarction, stroke and death from 
cardiovascular disease by 57% in the DCCT [8, 16]. The UKPDS similarly demonstrated 
the risk-reducing benefits of glycaemic control in the micro vasculature [11].
Section 1.3: Diabetic Cardiomyopathy
Decades ago. Rubier documented the existence of myocardial disease of unknown 
cause in four diabetic patients [20]. Since then, numerous studies, both epidemiological 
and clinical, have suggested the existence of a cardiomyopathy distinct to diabetics which 
is not caused by pre-existing heart conditions such as hypertension or coronary artery 
disease (CAD) [9, 17, 19, 21-23] and results from numerous alterations both structural 
and metabolic (Figure 1.1).
Section 1.3.1: Metabolic changes in diabetic cardiomyopathy
Hyperglycaemia can introduce a number of adverse alterations in metabolism, 
particularly substrate utilization, which could be an underlying mechanism leading to 
cardiomyopathy [24-26]. Although the normal heart is able to derive energy from 
multiple substrates including ketones, amino acids, carbohydrates and fatty acids, 
approximately 70% of ATP generation occurs via fatty acid oxidation and the remaining 
30% is provided by glucose and lactate [24, 27, 28], The diabetic myocardium however, 
uses fatty acid oxidation almost exclusively for energy production [29].
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Figure 1.1: Schematic diagram illustrating some of the known mechanisms 
underlying diabetic cardiomyopathy
Hyperglycaemia can induce a number of changes in the myocardium. Derangements in 
cardiac metabolism lead to fatty acids becoming the dominant substrate for oxidation. 
Once the supply of free fatty acids exceeds the demand, lipotoxicity can occur. Fatty acid 
oxidation can also introduce mitochondrial dysfunction and promote oxidative stress. The 
coronary arteries are subject to accelerated atherosclerosis and the small vessels undergo 
microangiopathy. Lastly, owing to hypertrophy and fibrosis, the architecture of the 
myocardium changes. Diastolic dysfunction, with or without systolic dysfunction, is the 
end result.
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Section 1.3.2: Fatty acid oxidation in the diabetic heart
Fatty acids play a vital role in maintaining the healthy cardiac myocyte and their 
intracellular levels are tightly regulated [30]. Fatty acids are used as fuels, ligands for 
nuclear transcription factors, mediators of intracellular signal transduction and they are 
essential components of biological membranes [28]. Abnormalities in fatty acid 
regulation can result in a number of pathologies not limited to cardiotoxicity. Under 
diabetic conditions, increased lipolysis in adipose tissue combined with lipoprotein 
synthesis in the liver releases substantially more free fatty acids into the circulation [31]. 
The heart adjusts to these new hyperlipidémie conditions by enhancing the expression of 
fatty acid metabolizing proteins thus promoting fatty acid utilization [30], In this manner, 
the cardiac muscle is initially able to compensate for the change in substrate availability 
however, sustained exposure to this environment can lead to dysfunction [32, 33], 
Moreover, if fatty acid supply exceeds the rate of their oxidation the subsequent 
accumulation of lipids leads to lipotoxicity in the heart [31, 34].
Section 1.3.3: PPAR-a activation
In the mammalian heart, the expression of proteins for fatty acid oxidation is 
increased in response to elevations of fatty acids. Gene expression is propagated by 
peroxisome proliferator-activated receptor (PPAR)-alpha [35, 36], PPAR-a regulated 
genes are involved in various steps of fatty acid metabolism. The increased expression of 
fatty acid metabolizing genes coupled with the increase in fatty acid availability is largely 
responsible for increased utilization of this substrate for energy [37-39]. PPAR-a 
activation causes decreased expression of genes involved in glucose uptake, glycolysis,
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and pyruvate oxidation [24, 40], Additionally, glucose uptake is dependent on insulin but 
impaired insulin functioning combined with reduced glucose transporter type 4 (GLUT4) 
proteins limit glucose availability in cardiomyocytes [41, 42]. In contrast fatty acids can 
enter the cardiac cells with ease, as they require no hormones. All these factors serve to 
further promote the complete dependence of the heart tissue on fatty acids.
Section 1.3.4: Functional and Structural Changes in Diabetic Cardiomyopathy
Cardiac complications typically involve the left ventricle, coronary arteries and 
the microvasculature [43]. Studies of biopsy specimens reveal morphological changes at 
the tissue level, chiefly myocyte hypertrophy and perivascular fibrosis. As such, 
hypertrophy and fibrosis are hallmarks of diabetic cardiomyopathy [44]. Hypertrophy is 
characterized by increased left ventricular mass, increased wall thickness, stiffness and 
reduced chamber size [45-47], Myocardial fibrosis can further lead to ventricular wall 
stiffness, reduced compliance, and impaired diastolic function thereby exacerbating 
cardiac injury [48]. Diabetes can also accelerate atherosclerosis leading to coronary and 
cerebral artery disease [15, 51, 52]. Systemic hyperglycaemia can damage small blood 
vessels and cause a thickening of the basement membrane (BM) and eventual rupture 
leading to reduced blood flow and leakage of proteins [53, 54], Although, many 
mechanisms of hyperglycaemia-induced cardiac damage have been proposed, including 
derangement in metabolism, the exact one(s) have not been clearly isolated [55].
Section 1.4: Fibrosis in the diabetic myocardium
In the heart, myocytes are surrounded by the cardiac extracellular matrix (ECM) 
which is primarily composed of collagen with smaller amounts of elastin, laminin and
proteoglycans among others [56, 57]. The dominant collagens are type I, accounting 
anywhere from 50-80%, and type III collagen, comprising around 10% of the ECM; the 
other collagens are present but to a much lesser degree [56, 57]. Collagen may also be 
involved in the transmission of force generated by cardiac muscle [58]. Characterized by 
excess collagen accumulation, myocardial fibrosis is believed to be a maladaptive 
response occurring independently of organ hypertrophy [48]. Although studies indicate 
that only 2-4% of the myocardium is collagen, even slight changes in collagen 
concentration can have substantial effects on the mechanical properties of the heart [56, 
57, 59, 60].
Increased ventricular stiffness resulting from elevated levels of collagens can 
inhibit myocyte recoil during cardiac relaxation resulting in aberrant ventricular filling 
and consequently stroke volume [61, 62], Increases in collagen content impair sarcomere 
extension and compromise the ability of the heart to generate adequate pressure for 
systemic perfusion [61, 62]. With these factors taken together, it is clear that fibrosis 
greatly jeopardizes myocardial function and not surprisingly, fibrosis is a leading cause 
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Figure 1.2 Functional consequences of myocardial fibrosis
Fibrosis is a typical feature of diabetic cardiomyopathy. Collagen levels are elevated in 
the diabetic heart and this starts a cascade event that culminates in cardiac dysfunction 
that could lead to heart failure. The stiffness and non-compliance of the heart hampers its 
mechanical abilities by limiting ventricular filling and preventing the complete extension 
of the sarcomeres. The left ventricle consequently struggles to generate the adequate level 
of pressure required for systemic perfusion.
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Section 1.5: Fibroblast Cell Involvement
Fibrosis is believed to be mediated by fibroblasts [63-67]. The precise manner in 
which hyperglycaemia stimulates increased collagen deposition by fibroblasts in cardiac 
tissue is not clearly understood [68]. One possibility is that high glucose up-regulates 
transforming growth factor (TGF)-pi expression leading to increased fibroblast 
proliferation [58, 65, 69-71], TGF-pi is a known fibrogenic factor and key regulator of 
inflammation and wound healing; it is released at wound sites where it recruits 
neutrophils, monocytes and fibroblasts to initiate tissue repair [69, 72]. It also plays a 
central role in the maintenance of the ECM and can induce the expression of ECM 
proteins including collagen from fibroblasts [58, 65, 72]. TGF-pl has also been 
demonstrated to induce differentiation of fibroblasts to myofibroblasts [58, 65, 72]. 
Fibroblasts are quiescent but they migrate and proliferate upon activation [72]. During 
the reparative process, tissue needs to be contracted and as a result a subpopulation of the 
fibroblasts will gain contractile properties that resemble those belonging to smooth 
muscle cells and this modulation allows the cell, now called a myofibroblast, to secrete 
greater amounts of collagen [69, 73, 74].
Section 1.6: Other mechanisms of fibrosis: MMPs and NF-kB
Maintenance and degradation of the extracellular matrix in the myocardium is 
regulated by matrix metalloproteinases (MMPs) which are regulated in turn by their 
inhibitors, tissue inhibitors of metalloproteinases (TIMPs) [75-80]. Modifications in the 
activities of either MMPs or TIMPs have marked effects on the architecture of the ECM 
in the myocardium. In the event of impaired MMP regulation an imbalance in collagen
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synthesis versus collagen degradation leads to the accumulation of fibrillar collagen and 
the appearance of myocardial fibrosis [75, 80].
Lastly, a transcription factor implicated in fibrosis is nuclear factor-icB (NF-kB) 
[81-84], When inactive, NF-kB is complexed to its inhibitor, inhibitor-KB (IkB) and is 
thus prevented from entering the nucleus [85, 86]. Activation of IkB kinase (IKK) by 
extracellular signals initiates the degradation of IkB [85, 86]. Phosphorylation of two 
serine residues of the IkB structure by IKK leads to ubiquitination and subsequent 
digestion by the proteasome. NF-kB becomes free to translocate into the nucleus and 
transcribe its associated genes [85-87]. Specifically, NF-kB is responsible for the 
activation of pro-inflammatory cytokines some of which, such as tumour necrosis factor- 
alpha (TNF- a), are elevated in the diabetic heart [81, 82, 85]. Pro-inflammatory 
cytokines can subsequently induce expression of other cytokines such as TGF-(11. 
Furthermore, the pro-fibrogenic effect of these cytokines may also include MMP 
activation [79].
Section 1.7: A Closer Look at Calpain
Calpains are one of three cysteine proteases; caspases and cathepsins are the other 
two. In response to calcium signaling, calpains direct cellular functioning by cleaving 
select proteins [88]. Calpain can exist in any one of fifteen different isoforms however; 
the two most well-characterized members of the calpain family in mammals are p-calpain 
(calpain-1) and m-calpain (calpain-2) [88, 89]. They differ only in calcium sensitivity and 
are ubiquitously distributed but their exact physiological function remains unknown. 
Calpain exists in the cytosol as an inactive enzyme and translocates to the membrane in
response to increases in cellular Ca levels [88-90]. Calpain activity is regulated by 
calpastatin, an endogenous inhibitor capable of reversible binding of the calpain 
molecules in the presence of calcium [90].
Section 1.7.1: Structure and Activation
Calpain-1 and calpain-2 are both heterodimers consisting of an 80 kDa catalytic 
subunit and a regulatory 30 kDa subunit [88], Although the 30 kDa subunit, encoded by 
the CAPN4 gene, is identical in both calpains, the catalytic subunit is encoded by 
different genes: human chromosome 11 for calpain-1 and human chromosome 1 for 
calpain-2 [88], Nonetheless, the subunits share 55-65% homology [88], Calpain
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activation is triggered by a Ca flux which causes inactive calpain to translocate to the 
plasma membrane where activation occurs in the presence of Ca2+ and phospholipids 
[89].
The crystal structure of calpain reveals four domains (I-IV) in the 80 kDa subunit. 
Domain II is subdivided into domains Ha and lib which surround the substrate binding 
cleft [88, 89], The 30 kDa subunit has an additional two domains (V-VI) [88, 89]. The 
first of a two-step mechanism of activation is the release of constraints imposed by 
interactions between the four domains of the 80 kDa subunit [88]. Upon Ca binding to 
domains IV, VI and III, domain I is released from VI and domain II is released from III 
resulting in the dissociation of the 80kDa subunit from the 30kDa subunit, a pre-requisite 
for the formation of the catalytic site in the second stage [88, 89]. In the inactive 
conformation of calpain, further domain interactions separate subdomains Ha from lib, a 
structural constraint that prevents the formation of an active cleft site [88]. The binding of
12
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two additional Ca ions in the second step, one to domain Ha and the other to domain 
lib, induces a conformational rearrangement vital for the formation of a functional 
catalytic site [88, 89].
Section 1.7.2: The Biological Role
Calpains constitute a highly conserved superfamily existing ubiquitously from 
humans to microorganisms and exist in all vertebrate cells examined thus far, suggesting 
a vital biological role [88]. Mammalian calpains sequenced to date have shown a high 
degree of homology in their amino acid sequences and there is little indication of 
alternative splicing in the expression of the calpain gene [88], By modulating the 
biological activity of their substrates, calpains influence a number of calcium-regulated 
cellular processes including signal transduction, cell cycle progression, apoptosis and 
cytoskeletal remodeling [90, 91].
Calpain is also able to cleave pro-caspase 3, 7, 8, 9 into inactive fragments and as 
such has been implicated in apoptosis [92], Calpain has attracted much attention due to 
the recent discovery of correlations between calpain gene mutations and human diseases. 
Deregulation of calpain has been implicated in a number of pathologies including 
secondary degeneration resulting from acute cellular stress, neuronal degeneration, 
Alzheimer’s disease, metastasis, muscular dystrophy, cataracts and diabetes [93-95]. 
Calpain inhibition has been found to be protective in ischaemia injury models as well 
[96], A recent study demonstrated that cardiac over-expression of calpain-1 is sufficient 
to cause heart failure in transgenic mice [93, 97]. Our lab recently showed that 
hyperglycaemia-induced calpain-1 activation, mediated through an NADPH oxidase-
13
14
dependent pathway, can lead to apoptosis through down-regulation of (Na, K)-ATPase 
activity in cardiomyocytes and in vivo diabetic hearts [92]. Calpain inhibition via 
calpastatin over-expression imparted an anti-apoptotic effect on cardiomyocytes.
Calpain knockout models have indicated important roles for calpain-4, the 
regulatory subunit, and also suggest m-calpain may be more important than p.-calpain for 
embryonic development [98]. Compared to capn4+/' mice which had normal viability and 
calpain activity, the capn4'A embryos, generated by disrupting expression of the 80kDa 
small subunit encoded by the calpain-4 gene (CAPN4), died by 11.5 days of gestation 
after exhibiting cardiovascular abnormalities at day 10.5 [98], These embryos also had no 
detectable calpain activity. Interestingly, in the embryonic stem cells, the RNA levels of 
the 80kDa subunit of both calpains were normal however, the corresponding polypeptides 
for each were nearly undetectable [98]. The results point to a role for the regulatory 
subunit critical to cell survival that is currently unknown.
Transgenic capn 1 mice had significant decreases in platelet aggregation. It 
appears that the presence of m-calpain can compensate for the lack of p-calpain and that 
m-calpain and p-calpain may have the same substrates [88]. Previous studies have 
established a physiological role for calpain in the degradation of polypeptides during 
platelet activation however in the calpain-1 knockout mice these same polypeptides had 
normal degradation patterns [96, 99, 100].
On the other hand, knockout of m-calpain has shown to be embryonically lethal 
[88], This observation raises a few issues. First that m-calpain, along with calpain-4, must 
play an essential role in embryonic development, perhaps certain cleavages, that calpain- 
1 does not. Alternatively, a lack of embryonic lethality after calpain-1 knockout may be
due to the relatively late expression of p-calpain during development meaning, it would 
not be involved in calpain-dependent cleavages required for continued growth thus 
assigning it a non-essential function in embryonic development [88].
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Section 1.7.3: Endogenous Regulation of Calpain Activity
Deregulation of calpain can lead to cellular damage and subsequent pathology 
[95, 99, 101]. Calpain activity is thus tightly regulated by calcium availability as well as 
an endogenous inhibitor, calpastatin. Calpastatin is an entirely unstructured protein; its 
polypeptide is in a random coil formation when not bound to calpain [90]. Despite the 
presence of only a single calpastatin gene in mammals, the use of at least four different 
promoters and alternative splicing mechanisms allow the production of different 
calpastatin polypeptides [88-90]. It appears that invertebrates do not possess the 
calpastatin gene; any regulation of calpain activity by calpastatin is limited to vertebrates 
[88]. No polypeptide sequenced thus far has homology to the calpastatin amino acid 
sequence [90, 97]. Calpastatin is the only known inhibitor specific for the calpains [90], 
Furthermore, calpastatin does not inhibit any other protease [88-91, 97].
Section 1.8: The db/db Mouse and Diabetic Cardiomyopathy
The db/db mouse was used to model Type 2 diabetes. The mouse has a point 
mutation in the gene encoding the leptin-receptor (LEPR) [102-105]. Leptin is a hormone 
that controls satiety and energy expenditure by acting on the hypothalamus through the 
LEPR. Without the receptor, leptin does not exert its effects and the db/db mouse mimics 
leptin deficiency and grows massively obese.
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As Aasum and colleagues noted, “the metabolic features of db/db mice are similar 
to the pathogenesis of type 2 diabetes in humans.” Specifically, initial insulin resistance 
is temporarily overcome by enhanced insulin secretion producing a state of 
hyperinsulinemia [102]. Inevitably, elevated levels of insulin cannot maintain 
normoglycaemia for long and in concert with dysfunctional changes in pancreatic p-cells, 
insulin levels fall and severe hyperglycaemia ensues [102, 105]. db/db mice are also 
reported to exhibit the characteristics of diabetic cardiomyopathy at 10-14 weeks of age 
[54, 104, 106]. As in the human heart during diabetes, the db/db heart is associated with a 
dependence on fatty acid oxidation for energy [107]. Derangements in cardiac 
metabolism progresses with age as do contractile impairments including diastolic 
dysfunction [106].
Section 1.9: Purpose of Study
Studies suggest that calpain activation may contribute to the progression of heart 
failure [91]. Calpains are implicated in ischaemia/reperfusion-induced cardiomyocyte 
apoptosis and cardiac over-expression of calpain-1 was sufficient to cause heart failure in 
transgenic mice [99]. In contrast, over-expression of calpastatin prevented troponin I 
degradation and improved contractile function in rat hearts subjected to 
ischaemia/reperfusion but also inhibited cardiac fibrosis in angiotensin-II induced mice as 
shown by Manabe and colleagues [100]. Although an association between calpain and 
cardiac dysfunction is clear, calpain over-activity in the context of diabetes has not been 
examined nor, is there a type 2 murine model over-expressing the calpastatin gene.
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Section 1.10: Hypothesis
Overexpression of calpastatin will impede development of myocardial fibrosis caused 
by elevations in calpain activity as a result of hyperglycaemia in a type 2 murine 
model.
Section 1.11: Objectives of Thesis
1. Use a LEPR deficient murine model, db/db, to generate transgenic db/db mice 
over-expressing the CAST gene (db/db-CAST) by crossing heterozygous db+/' 
mice with homozygous transgenic mice over-expressing rabbit CAST.
2. Assess heart tissues for indications of fibrosis. Determine if CAST over­
expression imparted an anti-fibrotic benefit to db/db-CAST hearts.
3. Understand the action of calpain and CAST in fibroblast cells and specifically 
their effect on fibroblast proliferation and differentiation to myofibroblasts.
4. Investigate whether CAST over-expression has any effect on impaired collagen 
turnover and inflammatory responses in the diabetic heart.
CHAPTER 2: METHODS AND MATERIALS
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Mice that are homozygous for the LEPR mutation are sterile [108], Therefore, to 
generate the desired db/db-CAST model, heterozygous mice of the BKS strain were 
crossed with homozygous transgenic mice over-expressing rabbit CAST of a C57BL/6
db/- +/- db/-
background. This cross can yield four possible genotypes: Lepr CAST , Lepr 
-/- -/- +/- -/- -/-
CAST , Lepr CAST , Lepr CAST , each with a 25% probability of occurrence 
(Figure 2.1). Mice with the first two genotypes, identified qualitatively by black fur 
colour, are crossed to yield the second filial generation. In addition to the FI genotypes, 
this cross can yield another four genotypes each with a 12.5% chance of occurrence:
-/- +/- -/- -/- db/db -/- db/db +/-
Lepr CAST , Lepr CAST , Lepr CAST , Lepr CAST . From this
db/db -/- db/db +/-
final cross, the db/db (Lepr CAST ), db/db-CAST (Lepr CAST ) and WT
7- -/-
(Lepr CAST ) mice used in this study are produced (Figure 2.2).
Section 2.1: Generation of the CAST Transgenic Model
Note: Leprdh dh' Leprdh", and Lepr denote homozygous (db/db) mice, heterozygous 





Figure 2.1: Schematic illustration representing the first filial cross
The db/db mouse is sterile. In order to produce db/db and db/db mice over-expressing the 
CAST gene (db/db-CAST), heterozygous db+" mice will be crossed with db+" CAST 
mice to yield four possible genotypes. Genotypes outlined in red were used in the second 
filial cross.
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L e p rdb/- C A S T  -/- (25%)
Le p rdb/- C A S T  +/~ (25%)
Leprdb/-CA ST+/- x Leprdb/‘ CAST
L e p r /_ C A S T  +/ ~ (12.5%)
Le p r c  C A S T  [12,5%]
L e p rdb/db C A S J  /-  (12.5%)
Leprdb/db C A S T+/_ t«.5%)
Figure 2.2: Schematic illustration representing the second filial cross and offspring
CAST transgenic offspring heterozygous for the LEPR mutation were crossed with 
heterozygous offspring without the CAST gene from the first generation. Four unique 
genotypes are produced with a 12.5% chance of occurrence in addition to the two FI 
genotypes, with are each produced with a 25% chance of occurrence. Genotypes outlined 
in red were used. Outlined in green are the common names for each genotype as they will 
be referred to in this study.
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To determine transgenic CAST over-expression, l-2mm of tail was obtained from 
three week old mice and digested overnight at 37°C in a solution of Proteinase K 
(0.222mg/mL, Sigma-Aldrich, MO, USA) and 1 mL PBND [50 mM KC1, lOmM Tris- 
HC1 (pH8.3), 2.5mM MgCl2-6H20, 0.1 mg/mL gelatin, 0.45% NP40, 0.45% Tween-20]. 
Proteinase K digests unwanted proteins, including nucleases, and keratin. Samples are 
then heated first at 50°C for 1.5 hours then at 100°C for 5 minutes to inactivate 
Proteinase K. Undigested material is pelleted after centrifugation (Eppendorf Centrifuge 
5702, NY, USA) for 10 minutes at 10008xg and 2pL of lysate is used for PCR.
A pair of primers specific for rabbit CAST mRNA, not for the mouse CAST gene, were 
used to amplify the transgenic rabbit CAST gene for 35 cycles (Px2 Thermal Cycler, 
Thermo Electron Corporation, OH, USA):
Forward CAST primer: 5’ GTTGGCTTAGGCTGCTTTTCGT 3’
Reverse CAST primer: 5’ CCAGACTCCGTGACACCCCTT 3’
The PCR reaction was set as follows:
12.5 pL 2X PCR Mastermix (Fermentas),
0.4 pL (25pM) forward and reverse CAST primer 
10.1 pL DEPC-treated water 
2 pL lysates 
25 pL Total Volume
Section 2.2: Genotyping
Samples were run on a 2% agarose gel (containing ethidium bromide (EtBr)) at 80 volts 
for 30 minutes and the signal was visualized under UV light.
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The calpain activity assay measures the fluorescence intensity of AMC (7-amino- 
4-methylcoumarin) cleaved from the peptide substrate, N-succinyl-LLVY-AMC 
(Cedarlane Laboratories, Burlington, Ontario). Heart tissue was placed in 250pL of lysis 
buffer [1M HEPES (pH 7.4), 50 mM CHAPS (5 mL), 1M 0.1% DTT (0.5mL), 5mM 
EDTA (20pL)] homogenized and centrifuged at 22680xg for 15 minutes. Supernatant 
was removed and protein concentration was measured using a DC Protein Kit (Bio-Rad) 
and the concentration of all samples was equalized by adding appropriate amounts of 
reaction buffer (63 mM imidazole-HCl, pH 7.3, 10 mM P-mercaptoethanol, 1 mM 
EDTA, and 10 mM EGTA). The samples were incubated for two hours at 37 °C in either 
reaction buffer with or without calcium chloride (5 pM or 5 mM) or reaction buffer with 
or without calcium chloride (5 pM or 5 mM) in addition to 5 pM of calpain inhibitor,
PD 150606 (Li et al., 2009). The fluorescence intensity of cleaved AMC was quantified 
with a multilabel reader (excitation, 360 nm; emission, 460 nm) (Victor 1420 Multilabel 
Counter, PerkinElmer, MA, USA) and calpain activity was determined as the difference 
between calcium-dependent and calcium-independent fluorescence. (Li et al., 2009).
Section 2.3: Calpain Activity
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Blood samples were collected and centrifuged at 907xg for 15 minutes at 4°C. Plasma 
samples were transferred and stored at -85 °C until use. An ELISA-based rat/mouse 
insulin kit was purchased from Millipore (St. Charles, MO) and used to conduct insulin 
measurements. Each well of the microtiter assay plate provided was washed three times 
with 300pL of wash buffer (50 mM Tris Buffered Saline with Tween-20) that was diluted 
10 fold using distilled water. Diluted wash buffer was decanted after each wash.
To designated standard and control wells: lOpL rat insulin standards were added in the 
following order of concentration: 0.2 ng/mL, 0.5 ng/mL, 1 ng/mL, 2 ng/mL, 5ng/mL and 
10 ng/mL. Additionally, 10 pL matrix solution (charcoal stripped pooled mouse serum) 
was also added.
To sample wells: 10 pL of the plasma samples were added.
Subsequent additions to both control and sample wells included:
• 10 pL assay buffer (0.05 M phosphosaline, pH 7.4, containing 0.025 M EDTA, 
0.08% sodium azide, and 1% BSA)
• 80 pL detection antibody (pre-titered biotinylated anti-insulin antibody)
The plate was then sealed and incubated for two hours at room temperature after which 
the solutions were decanted from the plate and each well was again washed three times 
with diluted wash buffer, 300 pL per wash. Subsequently, 100 pL of enzyme solution 
(pre-titered streptavidin-horseradish peroxidase conjugate in buffer) was added to each 
well and the plate was sealed and incubated for 30 minutes. The enzyme solution was
Section 2.4: Insulin measurement
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emptied out and each well was washed 6 times with 300pL of the diluted wash buffer per 
wash. Then 100 pL of substrate solution (3, 3’, 5, 5’-tetramethylbenzidine in buffer) was 
added to each well, the plate was covered until a blue colour formed in wells at which 
point 100 pL of the stop solution (0.3 M HC1) was added. Absorbance was read at 450 
nm and 590 nm in a microplate reader (Model 680 Microplate Reader, Bio-Rad, 
Hercules, CA, USA) and insulin was measured as the difference between the two.
Section 2.5: RNA Isolation and cDNA synthesis
Heart tissue was homogenized in 1 mL TRIzol reagent (Invitrogen, Burlington, Ontario) 
and chloroform (EMD Chemicals Inc., Gibbs Town, NJ, USA) was used to separate 
aqueous and organic phases before centrifugation at 14490xg for 15 minutes. Isopropyl 
alcohol (EMD Chemicals Inc., Gibbs Town, NJ, USA) was added to the aqueous phase 
then decanted to precipitate the RNA. Reagent alcohol (VWR International, Westchester, 
PA, USA) was added then decanted and the pellet was dissolved in DEPC-treated water. 
UV absorbance at 260 nm was used to measure total RNA and at 260:280 nm to measure 
and standardize sample purity using a spectrophotometer. To synthesize cDNA, 1 pL of 
oligo (dT) (0.5 pg/mL, Sigma Genosys, Oakville, Ontario) was added to 3 pL total RNA 
(3 pg), and denatured at 65°C for 10 minutes. A mixture of dNTP (Sigma Aldrich, MO, 
USA), reverse transcriptase (Sigma Aldrich, MO, USA) and reverse transcription buffer 
(Sigma Aldrich, MO, USA) were added to the samples followed by a 50 minute 
incubation at 37°C. The reaction was stopped by heating the sample at 65°C for 5
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minutes. DEPC-treated water was added to 20pL of cDNA to bring the total volume to 
180pL. cDNA samples were stored at -20°C.
Section 2.6: Qualitative Real Time RT-PCR
The reaction mixture was as follows:
10 pL 2X SYBR Green Taq MasterMix (Fermentas, CA, USA)
5 pL DEPC-treated water
0.5 pL Forward primer (50 pmol/L)
0.5 pL Reverse primer (50 pmol/L)
4 pL cDNA 
20 pL Total volume
GAPDH was the housekeeping gene used to normalize the data. Real-time RT-PCR was 
performed in the MiniOpticon Thermocycler (Bio-Rad Laboratories, Hercules, CA, 
USA). The primers (Sigma GenoSys, Oakville, ON, Canada) and temperature profiles
used are found in Table 2.1.
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Table 2.1 Primer Sequences and Temperature Profiles for Real Time RT-PCR
Primer Sequence (5’-**3’) PCR Conditions
Phase Temperature- Time
TGF-ßl (+) TT GCTTC AGCTCC AC AG AGA 
(-) TGGTTGTAGAGGGCAAGGAC
Initial Dénaturation 95°C- 10 minutes 
Dénaturation 95°C- 15 seconds 
Annealing 60°C- 30 seconds 
Extension 72°- 30 seconds
Osteopontin (+) GACGACGATGATGACGATGA 
(-) CCTCAGTCCATAAGCCAAGC
a-SMA (+) GTCCC AG AC AT C AGGGAGT A A 
(-) TCGGATACTTCAGCGTCAGGA
CAST (+) GTTGGCTTAGGCTGCTTTTCG 
(-) CCAGACTCCGTGACACCCCTT
Collagen 1 (+)ACGGCTGCACGAGTCACAC 
(-) GGCAGGCGGGAGGTCTT
Collagen III (+) GTTCTAGAGGATGGCTGTACT 
(-) TT GCCTT GCGT GTTT GAT ATT
TIMPl (+) ATTCAAGGCTGTGGGAAATG 
(-) CTCAGAGTACGCCAGGGAAC
TIMP2 (+) CACAGACTTCAGCGAATGGA 
(-) CTTGGGAAGCTTGAGAGTGG
TIMP3 (+) AGCTGGCAAAGGCTTAAACA 
(-) CAAGCTTCCAGCCAAACTTC
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Tissue was fixed in 10% formalin and then embedded in paraffin and 7 pm sections were 
cut and transferred to slides which were de-paraffinized in two changes of xylene and 
hydrated in two changes of 100% ethanol for 10 minutes, 95% ethanol for 3 minutes,
85% ethanol for 3 minutes and finally in 75% ethanol for 2 minutes. Slides were washed 
and placed in Picrosirius red solution for one hour then subsequently dehydrated in 
ethanol and cleared in xylene before being mounted in a resinous medium. Picrosirius red 
solution was comprised of 0.5g Sirius red (Cat#365548, Sigma-Aldrich, MO, USA) and 
500mL picric acid solution (Cat# P6744-1GA, Sigma-Aldrich, MO, USA). Sigma-Scan 
Pro software was used to quantify levels of collagen deposition. A total of 10 fields from 
each slide were analyzed with a 20X objective lens.
Section 2.8: Echocardiography
Mice were anaesthetized using a ketamine/xylazine (100/10 mg per kg body weight) 
combination injected intraperitoneally. Echocardiographic measurements were conducted 
using tissue Doppler imaging at Robarts Research Institute (London, Ontario). M-mode 
images were obtained and analyzed [106].
Section 2.9: Cardiac Fibroblast Cell Culture
Three month old mice were injected with 40pL heparin in a 1:40 dilution in distilled 
water. Thirty-minutes later, heart tissue was removed from mice, minced and washed 
three times with IX D-Hanks solution then incubated at 37°C with an enzyme mixture
Section 2.7: Collagen Staining
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prepared from 0.01 g collagenase type 2 (Worthington Biochemical Corp., Lakewood, NJ) 
and 0.006 g dispase (Roche Diagnostics, Mannheim, Germany) in 10 mL D-Hanks 
solution (Sigma-Aldrich, MO, USA) for forty-five minutes to digest tissue and liberate 
fibroblast cells. The enzyme/sample mixture was centrifuged for 5 min at 8xg (Eppendorf 
Centrifuge 5180R, NY, USA) after which the supernatant was discarded and the pelleted 
fibroblast cells were suspended in 3mL Dulbecco’s modified eagle medium (DMEM) 
(HyClone Laboratories, ThermoFisher Scientific, Utah, USA) supplemented with 10% 
FBS (Gibco, Invitrogen, Grand Island, NY, USA) and 100 pg/ml penicillin- 
streptomyocin (Invitrogen, Burlington, ON, Canada) and seeded in Falcon plates. After 
two hours of incubation at 37°C, the medium was replaced with 3mL of fresh medium.
Section 2.10: Cardiac Fibroblast Digestion and High Glucose Stimulation
Cardiac fibroblast cells were cultured for three days at which point the culture medium 
was removed and the cells were suspended in 2 mL of trypsin for 2 minutes in order to 
re-suspend cells that have adhered to the plate surfaces. The solution was then 
centrifuged for 5min at 8xg. The supernatant was discarded and the pellet was suspended 
in 2mL of culture medium. An equal number of cells was measured into the appropriate 
wells in a 96-well plate and incubated at 37°C. The next day, culture media is replaced 
with 1 OOpL of either normal or high glucose media and incubated for one additional day 
at 37°C. Normal glucose (5.5 mM) media is comprised of 50mL DMEM supplemented 
with 2% FBS and 100 pg/ml penicillin-streptomyocin. High glucose media, 33 mM, is 
prepared the same way except for the addition of 0.243g of D-glucose (dextrose) 
(Invitrogen, Burlington, ON, Canada).
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After high glucose stimulation, 15pL of MTT solution is added to all wells. MTT 
solution is prepared by mixing 5mg of MTT (Thiazolyl blue: 98% TLC, Sigma) and lmL 
of distilled water. The solution is stored at -20°C. Three to four hours after incubation 
with MTT solution at 37°C, the wells are decanted and 150pL dimethyl sulfoxide 
(DMSO) is added to each well. A multilabel reader is used to measure absorbance 
(540nm). Proliferation is assessed using the averaged ratios of high to normal glucose for 
each group.
Section 2.11: MTT Proliferation Assay
Section 2.12: MMP activity measurement
Fibroblasts were cultured and stimulated as described in Section 2.9 and 2.10. The 
supernatant of cell culture media was collected, centrifuged at lOOOrpm for 15 minutes 
and stored at -70°C until use. The fluorimetric SensoLyte® 390 Generic MMP Assay Kit 
(Anaspec, CA, Cat #72202) was used to measure MMP activity. As per the 
manufacturer’s instructions the samples were incubated with 1 mM (APMA) for two 
hours at 37°C. MMP substrate was diluted 1:100 in assay buffer and 50pL were added to 
samples and control wells. Additional assay buffer was added in order to bring the total 
volume to 50pL in control wells only. The samples were incubated at room temperature 
for 30 minutes and fluorescence intensity was measured at Ex/Em=330 nm/390 nm.
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Tissue was fixed in 10 % formalin and embedded in paraffin. Sections of 5 micron 
thickness were transferred to slides which were de-paraffinized in two changes of xylene 
and hydrated in two changes of 100% ethanol for 10 minutes, 95% ethanol for 3 minutes, 
85% ethanol for 3 minutes and finally in 75% ethanol for 2 minutes before being washed 
and placed in acidic toluidine blue solution. After three minutes, the slides were 
subsequently dehydrated in ethanol and cleared in xylene before being mounted in a 
resinous medium. Mast cell numbers were visually quantified using a light microscope at 
20x magnification.
Section 2.14: Statistical Analysis
The Student’s t-test was used to compare differences between two treatment groups. 
ANOVA followed by the Tukey test was performed to examine statistical differences 
across multiple groups. A value of p< 0.05 was considered statistically significant and
Section 2.13: Toluidine Blue Staining for Mast Cells
data are given as mean ± SD.
CHAPTER 3: RESULTS
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Section A: Characterization of the mouse model
3.1 Generation of CAST Transgenic Mice
Mice homozygous for the LEPR mutation are sterile [108]. To produce the 
desired db/db-CAST model, homozygous transgenic mice over-expressing rabbit CAST 
are bred with mice heterozygous for the LEPR mutation in two successive crosses. 
Homozygous (db/db) and heterozygous (db+/-) offspring are separated on account of 
body size. As demonstrated by Figure 3.1 A, a db/db mouse is twice as large as its 
heterozygous littermate. Among the db/db group, mice are screened for CAST 
overexpression by genotyping tissue obtained from mice tails upon weaning at three 
weeks of age (Figure 3. IB).
34
Figure 3.1: Characterization of WT, db/db and db/db-CAST mice
A) The picture depicts the qualitative differences between the three types of mice 
used in this study. Wildtype mice are grey (1). Heterozygous mice are black (2) 
and lean, db/db, and db/db-CAST mice are black and obese (3).
B) Genotyping. Tail samples were used to detect the presence of the rabbit CAST 
gene by PCR. A representative agarose gel for rabbit CAST gene from 9 different 
mice shows that lanes #1, 2, 5, 8 and 9 are positive and lane #3, 4, 6 and 7 are 
negative.
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3.2: Insulin Measurement and General Parameters
The db/db mouse is a type 2 diabetic model that exhibits many consequences of 
diabetes including hyperglycaemia, hyperinsulinaemia and hyperlipidaemia [102], At 
three months of age all db/db and db/db-CAST mice had high blood glucose defined as a 
blood glucose level exceeding 33mmol/L and was measured using a OneTouch glucose 
monitor. Body weight measurements do not show any significant difference in weight 
between db/db and db/db-CAST mice. Nor is there any significant difference in the 
weight of the heart (Table 3.1). To ensure differences in plasma insulin levels are not 
contributing to the results, insulin measurements were taken and found to be similar 
between db/db and db/db CAST groups (Figure 3.2).
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Table 3.1: Weight and Blood Glucose
Body Weight (g) Heart Weight (g) Blood Glucose
WT 35.06 ± 1.03 0.14 ±0.03 Normal
db/db 68.52 ±3.55 0.17 ±0.01 High (>33mmol)


















Figure 3.2: Insulin levels are similar in db/db and db/db CAST mice.
Measurements of insulin from both db/db and db/db CAST mice did not show any 
difference. Data are mean ± SD, n=5.
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3.3: Calpain activity is elevated in diabetic mice
An activity assay measuring calpain activity in heart tissues from WT and db/db 
mice showed a significant increase in calpain activity in db/db mice compared to control 
mice (Figure 3.3). This ensured the db/db mouse model would be appropriate in which to 
test our hypothesis regarding calpain hyperactivity.
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Figure 3.3: Diabetic hearts have elevated calpain activity.
Calpain activity assays confirm increased calpain activity in diabetic myocardia. Data are 
mean ± SD, n=5. *P <0.05 vs. WT.
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Section B: Myocardial Remodelling 
3.4: Collagen Deposition
Myocardial fibrosis is a typical feature of cardiomyopathy in the diabetic heart 
and is characterized by excessive production and accumulation of extracellular collagen 
[9, 10, 19, 22, 51]. Tissue was formalin-fixed and embedded in paraffin. Sections of 7 
micron thickness were de-paraffinized in xylene and rehydrated through graded alcohols 
then placed in Picrosirius red solution for one hour before mounting in a resinous 
medium. Collagen areas were manually traced using SigmaScan Pro software. The 
histological analysis revealed increased collagen deposition in db/db mice (0.035 ± 0.003 
area units) compared with the control group (0.02 ± 0.004 area units). Heart sections of 
db/db-CAST mice had significantly reduced collagen content (0.022 ±0.004 area units) 
(Figure 3.4).
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WT db/db db/db CAST
*
Control db/db db/db-CAST
Figure 3.4: Collagen deposition in the diabetic heart is reduced by CAST over­
expression
A) Representative micro-pictures for collagen staining from one out of five hearts in each 
group are presented. Collagen is highlighted by red staining (arrow, original 
magnification x20). B) Quantification of collagen content. The amount of collagen was 
assessed manually in 10 fields per tissue section and shown as the ratio between collagen 
quantified in the field and total area of the field. Data are mean ± SD, n=5/group.
*p<0.05.
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3.5: Gene Expression of Collagens I & III
In order to assess the impact of calpain hyperactivity on levels of collagens I and 
III, the major collagen types in the myocardium [56], heart tissues were analyzed using 
real time RT-PCR. Collagens I and III, expressed as a ratio of collagen I or III to the 
house-keeping gene, GAPDH, were up-regulated in db/db hearts but over-expression of 





WT db/db db/db CAST
Figure 3.5: CAST downregulates collagen I and III mRNA expression.
The mRNA levels of collagen I (A) and collagen III (B) in the myocardium were 
quantified by real time RT-PCR. Data are expressed as the ratio of Collagen I or III to 
GAPDH. Data are mean ± SD, n=l 1-13/group, *p<0.05.
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3.6: Collagen Ratios
The ratio of collagen I to collagen III at the mRNA level has also been reported as 
an indicator of fibrosis in the myocardium [109, 110]. In this study, there was a clear shift 
in the collagen ratio from db/db mice to db/db-CAST mice whose collagen ratio was 
equivalent to the control (Figure 3.6). Taken together, the results suggest calpain 






WT db/db db/db CAST
Figure 3.6: Collagen Ratios in the diabetic heart
Ratio of collagen I to collagen III at the mRNA level show that CAST maintains the 
necessary equilibrium between the two collagen types. Data are mean ± SD, n=l 1- 
13/group, *p<0.05.
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3.7: Left Ventricular (LV) Wall Thickness
Structural changes at the microscopic level can translate to macroscopic 
alterations of the entire organ [51]. Echocardiography was used to assess left ventricular 
wall thickness. Although not statistically significant, the results show greater wall 

























Figure 3.7: Diabetic hearts exhibit increased left ventricular wall thickness.
The LV wall thickness was assessed at the papillary level by echocardiography. Data are 
mean ± SD, n=6/group.
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3.8: Hyperglycaemia induces fibroblast proliferation
Fibroblasts are believed to be key mediators of fibrosis in the injured or failing 
heart [63, 64, 111]. In the diabetic, cardiac fibroblasts are exposed to sustained 
hyperglycaemia [67]. To understand the effect this would have on the fibroblast 
population in the myocardium, cardiac fibroblast cells from wildtype mice were cultured 
and subjected to either normal (5.5 mM) or high glucose treatments (30 mM). The use of 
cells isolated from wildtype mice ensures the results will not be complicated by the 
effects of pre-existing hyperglycaemia. Exposure to high glucose for 24 hours was 
sufficient to cause an increase in fibroblast proliferation. However, under the same 
hyperglycaemic conditions, proliferation was reduced by pharmacological calpain 
inhibition (Figure 3.8A). Cardiac fibroblasts from db/db mice were also cultured. 
Compared to the control group, the db/db group had higher proliferation regardless of 
glucose exposure, in vitro (Figure 3.8B). Increases in fibroblast proliferation became 
more pronounced upon 24 hour high glucose treatment, once again confirming 
hyperglycaemic conditions are sufficient to induce a proliferative response in cardiac 
fibroblast cells. These results suggest that fibroblast cells are more prone to proliferation 
in db/db mice whether in normal or high glucose medium implying greater fibroblast
Section C: Fibroblast Proliferation and Differentiation
activity in the diabetic myocardium.
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WT db/db
Figure 3.8: Proliferation of cardiac fibroblast cells from WT and db/db hearts.
Cardiac fibroblast cells were isolated from WT and db/db mouse hearts. Twenty-four 
hours after passaging, fibroblast cells were subjected to normal or high glucose for one 
day. An MTT assay was performed to assess cell proliferation. A) High glucose increased 
fibroblast proliferation which was reversed by calpain inhibitor-III (10 pM). Data are 
mean ± SD, n=4 *p<0.05. B) db/db cardiac fibroblasts were more proliferative than WT 
cardiac fibroblasts regardless of glucose treatment. Proliferation is expressed using 
arbitrary units. Data are mean ± SD, n=4.
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In order to elucidate the role calpain over-activity may play in provoking 
fibroblast proliferation, cardiac fibroblast cells from db/db and db/db-CAST mice were 
both cultured and incubated with normal and high glucose for one day. Proliferation was 
greater in db/db cells but significantly reduced by CAST over-expression in both 
treatments (Figure 3.9). Fibroblasts are the primary effectors of fibrosis and evidently, 
one likely target of calpain over-activity in hyperglycaemia.
3.9: Fibroblast proliferation is limited by CAST over-expression
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Figure 3.9: CAST over-expression limits fibroblast cell proliferation.
MTT assays of cultured cardiac fibroblast cells from db/db and db/db CAST mice shows 
CAST over-expression impedes proliferation of fibroblasts in diabetic murine hearts. 
Proliferation is calculated as a ratio of average high glucose to average normal glucose 
wells and expressed using arbitrary units. Data are mean ± SD, n=4, *p<0.05.
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TGF-pi is a known fibrogenic cytokine [58, 65]. To determine if TGF-pi is 
differentially expressed among the three experimental groups, heart tissues from WT, 
db/db and db/db CAST mice were subjected to real time RT-PCR. The mRNA levels of 
TGF-pi were increased in db/db mice. However, the increase was reduced to control 
levels by over-expression of CAST (Figure 3.10).
TGF-pi is known to induce differentiation of fibroblasts to myofibroblasts which 
have a higher capacity for collagen production [69, 72, 112]. During their formation, 
myofibroblasts irreversibly acquire proteins such as smooth muscle actin-alpha (a-SMA) 
making it a key indicator of fibroblast differentiation [113-115], Although the results did 
not reach significance, real time RT-PCR performed on heart tissue from the three groups 
indicate that a-SMA expression is increased in diabetic db/db hearts but not in db/db 
CAST hearts (Figure 3.11 A).
Another protein indicative of fibroblast differentiation is osteopontin (OPN) [1 lb- 
120]. OPN is involved in intracellular signals required to induce the proliferation and 
migration of Myofibroblasts [116, 120, 121]. As expected, OPN levels were highest in 
diabetic hearts but CAST reduced OPN expression (Figure 3.1 IB). Taken together the 
results suggest calpain inhibition prevents fibroblast differentiation.
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WT db/db db/db CAST
Figure 3.10: TGF-pi mRNA expression is up-regulated in the diabetic heart
The mRNA levels of TGF-pi in the diabetic heart were determined by real-time RT- 
PCR. Up-regulation of TGF-pi is seen in diabetic hearts however, CAST over­
expression leads to reduced TGF-pi levels. TGF-pi mRNA levels are expressed relative 






Figure 3.11: CAST inhibits fibroblast differentiation as indicated bya-SMA and 
OPN expression.
The mRNA levels of a-SMA (A) and OPN (B) in the heart were determined by real-time 
RT-PCR. mRNA expression is shown as a ratio of a-SMA or OPN to GAPDH. Data are 
mean ± SD, n= 8-11, *p<0.05.
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Section D: Collagen Turnover and Inflammation
3.11: CAST reverses MMP and TIMP imbalance
In order to determine if impaired collagen turnover may be a perpetuating factor 
in the development of fibrosis in the myocardium, MMP activity assays were performed 
on cultured cardiac fibroblast cells. As shown in Figure 3.12, MMP activity was 
consistently lower in the high glucose treated cells that inhibited cal pain either 
transgenically or pharmacologically using calpain-inhibitor III than in cells that were 
exposed only to a hyperglycaemic medium suggesting calpain and hyperglycaemia may 
work synergistically to increase MMP activity. The mRNA levels of TIMP 1 and TIMP2 
were measured in heart tissues collected from the three groups. As shown in Figure 3.13, 
the levels of both TIMP1 and TIMP2 mRNA were elevated in the diabetic group. 




Figure 3.12: High glucose mediates increased MMP activity in cultured cardiac 
fibroblast cells.
The activity level of MMPs were decreased in fibroblast cells cultured from the 
myocardium of transgenic mice over-expressing CAST and wildtype mice whose cells 





WT db/db db/db CAST
Figure 3.13: TIMP expression in diabetic db/db hearts
The mRNA levels of TIMP 1 and TIMP2 were quantified by real-time RT-PCR in the 
hearts of diabetic mice. Their mRNA expression is shown relative to GAPDH. Data is 
mean ± SD, n=3-6, *p<0.05.
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3.12: Mast cells in the diabetic heart
Mast cell infiltration is correlated with fibrosis in numerous organ systems [122, 
123]. It has been suggested that mast cells may potentiate fibroblast proliferation and may 
thus promote the progression to myocardial fibrosis in diabetes [123-126] . In this study, 
heart sections of 5 micron thickness were stained in toluidine blue and mast cell numbers 
were visually quantified at 20x magnification. The db/db mice had greater mast cell 
density than wildtype mice. However, as shown in Figure 3.14, CAST over-expression 
prevented mast cell infiltration in the diabetic heart.
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Figure 3.14 Mast cell hyperplasia is minimized by CAST over-expression.
Heart sections were stained using toluidine blue. A) A representative micro-picture for 
mast cell staining (arrow pointing to mast cells, purple-red colour signal) from 3-6 heart 
tissues in each group B) Mast cells were visually quantified at 20x magnification and 
expressed as the number of mast cells in each section. Data is mean ± SD, n=3-6, 
*p<0.05.
CHAPTER 4: DISCUSSION
Elevated calpain activity is a feature of the failing myocardium [91, 96, 101] . 
However, it has been relatively understudied as a potential mechanism underlying the 
maladaptive changes seen in the diabetic heart. This study demonstrated first that a 
successful animal model of type II diabetes over-expressing calpastatin could be 
generated in order to study the influence of calpain in diabetic heart failure. Second, 
collagen deposition is limited by calpastatin over-expression and may consequently 
hinder progression to heart dysfunction and eventual failure. Lastly, the fibroblast cell is 
one of the targets of calpain over-activity as calpastatin over-expression clearly prevented 
fibroblast activity including proliferation (Figure 4.1).
The db/db mouse exhibits the characteristic features of type 2 diabetes early in its 
life cycle [102, 103]. They become identifiably obese around three to four weeks of age. 
Elevation of blood glucose begins at four to eight weeks [102]. Initially, hyperglycaemia 
leads to insulin resistance and hyperinsulinemia [102, 103, 105]. Lipolysis and enhanced 
lipoprotein synthesis in the liver results in a greater supply of free fatty acids which 
eventually hijack cardiac metabolism [24-26]. Cardiac dysfunction appears soon after and 
becomes progressively more pronounced with age [106], The db/db and db/db-CAST 
mice had the same metabolic features. Both grew obese within three weeks and were 
hyperglycaemic at the time of sacrifice. There was no difference in body weight and heart 
weight between the two and no modified behaviour in db/db-CAST mice was observed. 
Previous studies in our lab and others have shown calpastatin over-expression does not 
interfere with calpain activity in normal physiologic conditions [90, 95, 97], Thus, the 
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Figure 4.1: Schematic diagram representing the different players influenced by 
calpain inhibition.
This study showed calpain inhibition reduced the amount of absolute collagen deposited 
in the ECM. A mechanistic study points to the involvement of mast cells, TGF-(3 in 
stimulating fibroblast activity. Modifications in collagen turnover may also be involved.
In this study, we demonstrated that inhibition of calpain activity via calpastatin 
over-expression was successfully able to inhibit the increase in collagen deposition seen 
in db/db hearts. Collagen is vital to the maintenance of cardiac architecture. Yet, slight 
increases in collagen content can translate into mechanical impairments [57, 127]. An 
echocardiograph also showed the thickness of the left ventricular wall to be decreased in 
db/db-CAST mice suggesting microscopic improvements were sufficient enough to cause 
structural changes in the whole organ. Furthermore, the decrease in collagen 
accumulation in the treatment group resulted in a collagen ratio equivalent to the one in 
the wildtype control group. Collagen I is characterized by tensile strength whereas 
collagen III has greater elastic potential [56], Thus, ratios between collagen types are 
significant as they may have a substantial impact on the diastolic and systolic function of 
the heart [110, 127]. Clearly as calpain over-activity is restrained, the amount of total 
collagen accumulation in the hyperglycaemic heart is diminished and the relative 
amounts of collagens I and III are brought back to homeostatic levels.
Having established a correlation between calpain activity and collagen content in 
the myocardium, we isolated and cultured cardiac fibroblast cells from all three groups of 
mice and subjected each set to high and normal glucose treatments. Many biological 
mechanisms thought to contribute to or cause myocardial fibrosis point in some way to 
the involvement of the fibroblast cell [63, 65, 74, 128], The fibroblast is hard to ignore; it 
is the cell type largely responsible for maintaining the extracellular matrix [56, 57]. The 
study aimed to identify fibroblasts as targets of calpain hyperactivity and examine the 
mechanisms that relate calpain to fibroblast stimulation. Results showed a significant 
increase in proliferation under the influence of hyperglycaemia, not surprising since they
are a significant cell population in organs commonly affected by diabetes including the 
kidney and liver [63, 129], The novel finding proved to be the effect of calpastatin on 
fibroblast proliferation. In comparison, cultured fibroblast cells from db/db-CAST mice 
had consistently reduced levels of fibroblast proliferation than db/db mice. Furthermore, 
when wildtype fibroblast cultures were subjected to high glucose in addition to a 
pharmacological calpain inhibitor, they mirrored the results from db/db-CAST cultures 
with a drop in proliferation compared to wildtype fibroblast cells that had been treated 
only with high glucose. Because the calpain inhibitor used is not entirely specific for 
calpain but also a number of other proteases, the results have their limitations. However, 
combined, the effects of calpastatin over-expression and pharmacological calpain 
inhibition make a compelling case for an association between fibroblast activation and 
calpain activity.
TGF-pi has gained notoriety as a potent fibrogenic cytokine [65]. Upon tissue 
injury, it can spur fibroblasts into action by stimulating the release of ECM proteins, 
particularly collagen, and initiate wound healing and repair [58]. But further research 
into the mechanisms behind fibrosis has highlighted its ability to promote excess and 
secretion of collagen from fibroblasts [58, 65, 71, 72]. Among its pro-fibrotic abilities, 
TGF-fS can induce the differentiation of fibroblasts to specialized contractile fibroblasts 
called myofibroblasts [70, 72, 74], Over the course of their development, myofibroblasts 
irreversibly acquire proteins, one of which is a-SMA, a well-accepted marker of 
myofibroblast differentiation [113-115]. Another marker is OPN which coordinates 
intercellular signals required to integrate myofibroblast proliferation, migration and ECM 
deposition [117-120, 130-133]. OPN may require its secretion by myofibroblasts, and
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may promote differentiation [120, 133]. This study showed an up-regulation of TGF-p in 
db/db mice as expected but in the calpastatin over-expression group the expression of 
TGF-P was reduced. The expression of a-SMA and OPN showed the same trend 
suggesting calpastatin prevented TGF-P stimulation and consequently prevents the 
cytokine from stimulating fibroblast differentiation.
Being a key pro-inflammatory cytokine, TGF-P 1 can induce mast cell chemotaxis 
[82, 134-136]. Mast cell infiltration is a common observation in tissue repair processes 
regardless of the underlying diagnosis [137, 138]. Hearts from db/db mice showed 
increased mast cell density in tissue sections than db/db CAST mice indicating the 
involvement of calpain at some point in the inflammatory process. Previous studies, in 
vitro, have showed that mast cells may enhance fibroblast viability when co-cultured 
[137]. Interestingly, mast cells are a major source of TGF-pI and TNF-a for example, and 
may stimulate fibroblast activity through these secretion products [137, 139]. Yet, the 
exact relationship between mast cells and fibroblasts is still under examination.
Collagen synthesis is driven by fibrogenic factors, especially TGF-P, acting at the 
transcriptional level. However, collagen degradation is regulated by the MMP 
superfamily and impaired collagen turnover is a perpetuating factor in the development of 
myocardial fibrosis [76-80]. This study shows that stimulation by calpain is not limited 
only to the fibroblast, whether directly or indirectly through fibrogenic factors, but also to 
the remodelling machinery in the ECM. MMP levels were increased in the fibroblast cells 
of wildtype mice exposed to high glucose but not in the fibroblast cells of calpastatin 
transgenic mice. Wildtype fibroblast cells treated with calpain inhibitor III did not 
demonstrate an increase in MMP activity either thus highlighting the multidimensional
role of calpain in promoting the fibrotic phenotype. MMP production is regulated by 
TIMPs. In agreement with the results of our study, elevations in TIMP expression are a 
confirmed occurrence in diabetes [75, 140], Yet, we showed that with calpastatin over­
expression levels of TIMPs were reduced (TIMP1) or returned to normal levels (TIMP2).
This study has shown calpain inhibition as an effective means of decreasing total 
collagen accumulation in the diabetic heart. Experiments designed to understand the 
mechanisms responsible for the ability of calpain to promote fibrosis under 
hyperglycaemic conditions have pointed to over-activation of fibroblasts and the 
signalling pathways affecting fibroblast function. Derangements in MMP activity and 
stimulation of the immune response may also play a concerted role in the development of 
fibrosis in diabetic cardiomyopathy [134],
There are limitations in using mice to model human heart disease, a major one 
being the much higher heart rate and basal systolic contraction levels in the murine heart 
and the difference in resident cell populations in the myocardium across species [102]. 
But although the cardiac phenotype present in the mouse cannot be extrapolated to the 
human diabetic in its entirety, the fact that rodents are not susceptible to atherosclerosis is 
a major boon in their use because a diabetic model without any complicating coronary 
artery disease provides a suitable backdrop to examine the evidence of a cardiomyopathy 
unique to diabetics [102]].
CHAPTER 5: FUTURE STUDIES
Collagen deposition was consistently decreased in db/db CAST mice. 
Undoubtedly, this should restore some measure of function to the myocardium. The most 
obvious next step should consist of a functional study using echocardiography or 
perfusion techniques to determine if the myocardia from mice over-expressing calpastatin 
have improved mechanical properties compared to db/db mice.
In the course of cellular metabolism, mitochondria generate numerous reactive 
oxygen species such as superoxide; highly reactive and capable of damaging nucleic 
acids and protein structure [44, 141-144], The cell has numerous antioxidant defense 
mechanisms however, should ROS production exceed ROS elimination, oxidative stress, 
another hallmark event in the course of diabetic cardiomyopathy, will ensue [145-149]. A 
transcription factor, NF-kB, is implicated in promoting fibrosis by enhancing ROS 
production [81, 150]. NF-kB is also an important mediator of the inflammatory response 
and activates numerous cytokines including TGF-[3 and TNF-a and participates in the 
recruitment of immune cells, including mast cells [151, 152], Its activation is initiated by 
the degradation of its inhibitor, IkB which can be accomplished by calpain [153]. Thus, it 
could prove worthwhile to measure NF-kB activity by extracting nuclei from all three 
groups of mice to determine if NF-kB activity is down-regulated by calpastatin. Further, 
in previous studies in our lab we demonstrated that hyperglycaemia is associated with 
increased activity of calpain in mitochondria in a type 1 diabetes model. The same 
approach can be used to determine if increased mitochondrial calpain plays a causal role 
in raising whole cell ROS production in a type 2 model.
Arguably, the greatest leap in understanding the calpain/calpastatin system would 
come with a precise account of the biological roles calpain performs and upon which
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substrates it acts. Unfortunately, this task is complicated for a number of reasons. Calpain 
is distributed throughout the cytosol and as result has no association with a specific 
organelle that would hint to its purpose [88, 89]. Nor is the amino acid sequence of any 
calpain isoform indicative of its substrate because calpain functions conformationally 
[88, 89]. The protease is also difficult to purify in an undegraded form [75]. Another 
significant obstacle in determining calpain function experimentally is that the calcium 
requirement for calpain activation in experiments is much higher than physiological 
concentrations found in living cells rendering laboratory studies difficult [88, 89]. 
However, continued research on the calpain molecule itself and indirect studies on the 
consequences of altered calpain activity in various pathologies, such as this study on 
diabetic cardiomyopathy, should provide a clearer picture of this protease’s elusive 
properties.
CHAPTER 6: SIGNIFICANCE OF STUDY
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Cases of diabetes continue to rise despite awareness initiatives and extensive 
research into its cause and treatment [1-4]. Rising obesity rates, sedentary lifestyles and 
an aging population are all contributing factors. Though the economic cost is enormous, 
the cost to patients is greater [4]. The ultimate goal is to find ways in which diabetes can 
be cured. However, this goal is complicated by the introduction of numerous related 
illnesses and pathologies especially diabetic cardiomyopathy[2-4]. This study 
demonstrated, for the first time, that hyperglycaemia-induced fibrosis in the myocardium 
can be reversed or inhibited by calpain inhibition. Yet, this only scratches the surface as 
calpain activation has been shown to have key importance in the promotion and 
development of the fibrotic phenotype not only in the diabetic but all patients of heart 
disease [95, 97, 99, 101, 154]. Additionally, understanding the calpain-calpastatin system 




1. Diabetes Fact Sheet 2007, Department of Health and Human Services Centers for 
Disease Control and Prevention. National USA.
2. Diabetes in Canada -  Facts and Figures, in National Diabetes Fact Sheets200%, 
Public Health Agency of Canada: Canada.
3. IDF Diabetes Atlas, 2009, International Diabetes Federation: Brussels, Belgium.
4. The Prevalence and Costs o f  Diabetes 2010, Canadian Diabetes Association.
5. Jauregui, G.R., [Types o f  diabetes mellitus in man and diabetes mellitus in 
endocrine diseases]. Sem Med, 1954. 105(22): p. 1005-16.
6. Laakso, M., Hyperglycemia and cardiovascular disease in type 2 diabetes. 
Diabetes, 1999. 48(5): p. 937-42.
7. Abbott, R.D., et al., The impact o f  diabetes on survival following myocardial 
infarction in men v.v women. The Framingham Study. JAMA, 1988. 260(23): p. 
3456-60.
8. Calles-Escandon, J., et al., Effect o f  intensive compared with standard glycemia 
treatment strategies on mortality by baseline subgroup characteristics: the Action 
to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care, 
2010. 33(4): p. 721-7.
9. Fang, Z.Y., J.B. Prins, and T.H. Marwick, Diabetic cardiomyopathy: evidence, 
mechanisms, and therapeutic implications. Endocr Rev, 2004. 25(4): p. 543-67.
10. Khavandi, K., et al., Diabetic cardiomyopathy—a distinct disease? Best Pract Res 
Clin Endocrinol Metab, 2009. 23(3): p. 347-60.
11. Stettler, C., et al., Glycemic control and macrovascular disease in types 1 and 2 
diabetes mellitus: Meta-analysis o f  randomized trials. Am Heart J, 2006. 152(1): 
p. 27-38.
12. Nathan, D.M., et al., Intensive diabetes treatment and cardiovascular disease in 
patients with type 1 diabetes. N Engl J Med, 2005. 353(25): p. 2643-53.
13. Kannel, W.B., Lipids, diabetes, and coronary heart disease: insights from the 
Framingham Study. Am Heart J, 1985. 110(5): p. 1100-7.
14. Kannel, W.B., Framingham study insights on diabetes and cardiovascular 
disease. Clin Chem, 2011. 57(2): p. 338-9.
15.
73
Wilson, P.W., K.M. Anderson, and W.B. Kannel, Epidemiology o f  diabetes 
mellitus in the elderly. The Framingham Study. Am J Med, 1986. 80(5A): p. 3-9.
16. Liakishev, A.A., [Intensive diabetes treatment and cardiovascular disease in 
patients with type 1 diabetes. Results o f  the DCCT/EDIC study], Kardiologiia, 
2006. 46(3): p. 73.
17. Aneja, A., et al., Diabetic cardiomyopathy: insights into pathogenesis, diagnostic 
challenges, and therapeutic options. Am J Med, 2008. 121(9): p. 748-57.
18. Battiprolu, P.K., et ah, Diabetic Cardiomyopathy: Mechanisms and Therapeutic 
Targets. Drug Discov Today Dis Mech, 2010. 7(2): p. el35-el43.
19. Bell, D.S., Diabetic cardiomyopathy. A unique entity or a complication o f 
coronary artery disease? Diabetes Care, 1995. 18(5): p. 708-14.
20. Rubier, S., et ah, New type o f  cardiomyopathy associated with diabetic 
glomerulosclerosis. Am J Cardiol, 1972. 30(6): p. 595-602.
21. Boudina, S. and E.D. Abel, Diabetic cardiomyopathy revisited. Circulation, 2007. 
115(25): p. 3213-23.
22. Falcao-Pires, I. and A.F. Leite-Moreira, Diabetic cardiomyopathy: understanding 
the molecular and cellular basis to progress in diagnosis and treatment. Heart 
Fail Rev, 2011.
23. Maisch, B., P. Alter, and S. Pankuweit, Diabetic cardiomyopathy—fact or fiction? 
Herz, 2011. 36(2): p. 102-15.
24. An, D. and B. Rodrigues, Role o f  changes in cardiac metabolism in development 
o f diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol, 2006. 291(4): p. 
H1489-506.
25. Chatham, J.C. and J.R. Forder, Relationship between cardiac function and 
substrate oxidation in hearts o f  diabetic rats. Am J Physiol, 1997. 273(1 Pt 2): p. 
H52-8.
26. Lopaschuk, G.D., Metabolic abnormalities in the diabetic heart. Heart Fail Rev, 
2002. 7(2): p. 149-59.
27. Augustus, A.S., et ah, Routes o f  FA delivery to cardiac muscle: modulation o f  
lipoprotein lipolysis alters uptake ofTG-derived FA. Am J Physiol Endocrinol 
Metab, 2003. 284(2): p. E331-9.
28. Lopaschuk, G.D., et ah, Regulation o f fatty acid oxidation in the mammalian 
heart in health and disease. Biochim Biophys Acta, 1994. 1213(3): p. 263-76.
29.
74
Taegtmeyer, H., R. Hems, and H.A. Krebs, Utilization o f  energy-providing 
substrates in the isolated working rat heart. Biochem J, 1980. 186(3): p. 701-11.
30. Unger, R.H. and L. Orci, Diseases ofliporegulation: new perspective on obesity 
and related disorders. FASEB J, 2001. 15(2): p. 312-21.
31. Chiu, H.C., et al., A novel mouse model oflipotoxic cardiomyopathy. J Clin 
Invest, 2001. 107(7): p. 813-22.
32. Temsah, R.M., et al., Modulation o f  cardiac sarcoplasmic reticulum gene 
expression by lack o f  oxygen and glucose. FASEB J, 2001. 15(13): p. 2515-7.
33. Zhou, Y.T., et al., Lipotoxic heart disease in obese rats: implications for human 
obesity. Proc Natl Acad Sci U S A ,  2000. 97(4): p. 1784-9.
34. Sharma, S., et al., Intramyocardial lipid accumulation in the failing human heart 
resembles the lipotoxic rat heart. FASEB J, 2004. 18(14): p. 1692-700.
35. Barger, P.M. and D.P. Kelly, PPAR signaling in the control o f  cardiac energy 
metabolism. Trends Cardiovasc Med, 2000. 10(6): p. 238-45.
36. Kersten, S., Peroxisome proliferator activated receptors and lipoprotein 
metabolism. PPAR Res, 2008. 2008: p. 132960.
37. Gulick, T., et al., The peroxisome proliferator-activated receptor regulates 
mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci U 
S A, 1994.91(23): p. 11012-6.
38. Leone, T.C., C.J. Weinheimer, and D.P. Kelly, A critical role for the peroxisome 
proliferator-activated receptor alpha (PPARalpha) in the cellular fasting 
response: the PPARalpha-null mouse as a model o f  fatty acid oxidation disorders. 
Proc Natl Acad Sci U S A ,  1999. 96(13): p. 7473-8.'
39. Mandard, S., M. Muller, and S. Kersten, Peroxisome proliferator-activated 
receptor alpha target genes. Cell Mol Life Sci, 2004. 61(4): p. 393-416.
40. Ferre, P., Regulation o f gene expression by glucose. Proc Nutr Soc, 1999. 58(3): 
p. 621-3.
41. Armoni, M., et al., Free fatty acids repress the GLUT4 gene expression in cardiac 
muscle via novel response elements. J Biol Chem, 2005. 280(41): p. 34786-95.
42. Camps, M., et al., Effect o f  diabetes and fasting on GLUT-4 (muscle/fat) glucose- 
transporter expression in insulin-sensitive tissues. Heterogeneous response in 
heart, red and white muscle. Biochem J, 1992. 282 ( Pt 3): p. 765-72.
43.
75
Bourajjaj, M., et al., NFATc2 is a necessary mediator o f  calcineurin-dependent 
cardiac hypertrophy and heart failure. J Biol Chem, 2008. 283(32): p. 22295-303.
44. Khullar, M., et al., Oxidative stress: a key contributor to diabetic 
cardiomyopathy. Can J Physiol Pharmacol, 2010. 88(3): p. 233-40.
45. Colella, M., et al., Ca2+ oscillation frequency decoding in cardiac cell 
hypertrophy: role o f  calcineurin/NFATas Ca2+ signal integrators. Proc Natl 
Acad Sci U S A ,  2008. 105(8): p. 2859-64.
46. Cosson, S. and J.P. Kevorkian, Left ventricular diastolic dysfunction: an early 
sign o f  diabetic cardiomyopathy? Diabetes Metab, 2003. 29(5): p. 455-66.
47. Voulgari, C., D. Papadogiannis, and N. Tentolouris, Diabetic cardiomyopathy: 
from the pathophysiology o f  the cardiac myocytes to current diagnosis and 
management strategies. Vase Health Risk Manag, 2010. 6: p. 883-903.
48. Asbun, J. and F.J. Villarreal, The pathogenesis o f  myocardial fibrosis in the 
setting o f  diabetic cardiomyopathy. J Am Coll Cardiol, 2006. 47(4): p. 693-700.
49. Lorenz, K., et al., A new type o f  ERKl/2 autophosphorylation causes cardiac 
hypertrophy. Nat Med, 2009. 15(1): p. 75-83.
50. McKinsey, T.A. and D.A. Kass, Small-molecule therapies for cardiac 
hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov, 2007. 6(8): 
p. 617-35.
51. Taegtmeyer, H., P. McNulty, and M.E. Young, Adaptation and maladaptation o f  
the heart in diabetes: Part 1: general concepts. Circulation, 2002. 105(14): p. 
1727-33.
52. Young, M.E., P. McNulty, and H. Taegtmeyer, Adaptation and maladaptation o f  
the heart in diabetes: Part II: potential mechanisms. Circulation, 2002. 105(15): 
p. 1861-70.
53. Farhangkhoee, H., et al., Vascular endothelial dysfunction in diabetic 
cardiomyopathy: pathogenesis and potential treatment targets. Pharmacol Ther, 
2006.111(2): p.384-99.
54. Severson, D.L., Diabetic cardiomyopathy: recent evidence from mouse models o f  
type 1 and type 2 diabetes. Can J Physiol Pharmacol, 2004. 82(10): p. 813-23.
55. Lebeche, D., A.J. Davidoff, and R.J. Hajjar, Interplay between impaired calcium 
regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nat 
Clin Pract Cardiovasc Med, 2008. 5(11): p. 715-24.
56.
76
Bosman, F.T. and I. Stamenkovic, Functional structure and composition o f  the 
extracellular matrix. J Pathol, 2003. 200(4): p. 423-8.
57. Brower, G.L., et al., The relationship between myocardial extracellular matrix 
remodeling and ventricular function. Eur J Cardiothorac Surg, 2006. 30(4): p. 
604-10.
58. Khan, R. and R. Sheppard, Fibrosis in heart disease: understanding the role o f  
transforming growth factor-beta in cardiomyopathy, valvular disease and 
arrhythmia. Immunology, 2006. 118(1): p. 10-24.
59. Candido, R., et al., A breaker o f  advanced glycation end products attenuates 
diabetes-induced myocardial structural changes. Circ Res, 2003. 92(7): p. 785-
92.
60. Diez, J.B., L.; Gonzalez, A.; Querejeta, R., The role o f  myocardial collagen 
network in hypertensive heart disease. Current Hypertension Reviews, 2007. 3: p. 
1-7.
61. Gonzalez, A., et al., Regulation o f  myocardial fibrillar collagen by angiotensin II. 
A role in hypertensive heart disease? J Mol Cell Cardiol, 2002. 34(12): p. 1585-
93.
62. Martos, R., et al., Diastolic heart failure: evidence o f  increased myocardial 
collagen turnover linked to diastolic dysfunction. Circulation, 2007. 115(7): p. 
888-95.
63. Brown, R.D., et al., The cardiac fibroblast: therapeutic target in myocardial 
remodeling and failure. Annu Rev Pharmacol Toxicol, 2005. 45: p. 657-87.
64. Fredj , S.B., J.; Louault, C.; Potreau, D., Interactions between cardiac cells 
enhance cardiomyocyte hypertrophy and increase fibroblast proliferation. Journal 
of Cellular Physiology, 2005. 202: p. 891-899.
65. Leask, A., TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovasc 
Res, 2007. 74(2): p. 207-12.
66. Petrov, V.V., R.H. Fagard, and P.J. Lijnen, Stimulation o f  collagen production by 
transforming growth factor-beta 1 during differentiation o f  cardiac fibroblasts to 
myofibroblasts. Hypertension, 2002. 39(2): p. 258-63.
67. Tokudome, T., et al., Direct effects o f  high glucose and insulin on protein 
synthesis in cultured cardiac myocytes and DNA and collagen synthesis in 
cardiac fibroblasts. Metabolism, 2004. 53(6): p. 710-5.
68. Neumann, S., et al., Aldosterone and D-glucose stimulate the proliferation o f  
human cardiac myofibroblasts in vitro. Hypertension, 2002. 39(3): p. 756-60.
69. Brown, R.D.M., M.D.; Long, C.S., Proinflammatory cytokines and cardiac 
extracellular matrix: regulation o f  fibroblast phenotype, in Interstitial Fibrosis in 
Heart Disease, F.J. Villarreal, Editor 2004, Springer: New York. p. 57-81.
70. Hinz, B., Formation and function o f  the myofibroblast during tissue repair. J 
Invest Dermatol, 2007. 127(3): p. 526-37.
71. Leask, A., Potential therapeutic targets fo r cardiac fibrosis: TGFbeta, 
angiotensin, endothelin, CCN2, and PDGF\ partners in fibroblast activation. Circ 
Res, 2010. 106(11): p. 1675-80.
72. Hinz, B., et al., The myofibroblast: one function, multiple origins. Am J Pathol, 
2007. 170(6): p. 1807-16.
73. Follonier Castella, L., et al., Regulation o f  myofibroblast activities: calcium pulls 
some strings behind the scene. Exp Cell Res, 2010. 316(15): p. 2390-401.
74. Hinz, B. and G. Gabbiani, Fibrosis: recent advances in myofibroblast biology and 
new therapeutic perspectives. F1000 Biol Rep, 2010. 2: p. 78.
75. Li, Q., et al., The roles o f  MMP-2/TIMP-2 in extracellular matrix remodelling in 
the hearts o f  STZ-induced diabetic rats. Acta Cardiol, 2007. 62(5): p. 485-91.
76. Lopez, B., A. Gonzalez, and J. Diez, Role o f  matrix metalloproteinases in 
hypertension-associated cardiac fibrosis. Curr Opin Nephrol Hypertens, 2004. 
13(2): p. 197-204.
77. Spinale, F.G., et al., A matrix metalloproteinase induction/activation system exists 
in the human left ventricular myocardium and is upregulated in heart failure. 
Circulation, 2000.102(16): p. 1944-9.
78. Uemura, S., et al., Diabetes mellitus enhances vascular matrix metalloproteinase 
activity: role o f  oxidative stress. Circ Res, 2001. 88(12): p. 1291-8.
79. Westermann, D., et al., Contributions o f  inflammation and cardiac matrix 
metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role 
o f angiotensin type 1 receptor antagonism. Diabetes, 2007. 56(3): p. 641-6.
80. Wilson, E.M. and F.G. Spinale, Myocardial remodelling and matrix 
metalloproteinases in heart failure: turmoil within the interstitium. Ann Med, 
2001. 33(9): p. 623-34.
77
78
81. Hamid, T., et al., Cardiomyocyte NF-{kappa}Bp65promotes adverse remodeling, 
apoptosis and endoplasmic reticulum stress in heart failure. Cardiovasc Res, 
2010.
82. Nian, M., et al., Inflammatory cytokines andpostmyocardial infarction 
remodeling. Circ Res, 2004. 94(12): p. 1543-53.
83. Onai, Y., et al., Inhibition ofNF-{kappa}B improves left ventricular remodeling 
and cardiac dysfunction after myocardial infarction. Am J Physiol Heart Circ 
Physiol, 2007. 292(1): p. H530-8.
84. Van der Heiden, K., et al., Role o f  nuclear factor kappaB in cardiovascular health 
and disease. Clin Sci (Lond), 2010. 118(10): p. 593-605.
85. Karin, M., The NF-kappa B activation pathway: its regulation and role in 
inflammation and cell survival. Cancer J Sci Am, 1998. 4 Suppl 1: p. S92-9.
86. Locke, M. and J. Anderson, NF-kappaB activation in organs from STZ-treated 
rats. Appl Physiol Nutr Metab, 2011. 36(1): p. 121-7.
87. Bours, V., et al., NF-kappaB activation in response to toxical and therapeutical 
agents: role in inflammation and cancer treatment. Toxicology, 2000. 153(1-3): 
p. 27-38.
88. Goll, D.E., et al., The calpain system. Physiol Rev, 2003. 83(3): p. 731-801.
89. Suzuki, K., et al., Structure, activation, and biology o f  calpain. Diabetes, 2004. 53 
Suppl 1: p. S12-8.
90. Hanna, R.A., R.L. Campbell, and P.L. Davies, Calcium-bound structure o f  
calpain and its mechanism o f  inhibition by calpastatin. Nature, 2008. 456(7220): 
p. 409-12.
91. Heidrich, F.M. and B.E. Ehrlich, Calcium, calpains, and cardiac hypertrophy: a 
new link. Circ Res, 2009. 104(2): p. el9-20.
92. Li, Y., et al., Calpain activation contributes to hyperglycaemia-induced apoptosis 
in cardiomyocytes. Cardiovasc Res, 2009. 84(1): p. 100-10.
93. Galvez, A.S., et al., Cardiomyocyte degeneration with calpain deficiency reveals 
a critical role in protein homeostasis. Circ Res, 2007. 100(7): p. 1071-8.
94. Kuwako, K., et al., Activation o f  calpain in cultured neurons overexpressing 
Alzheimer amyloid precursor protein. Brain Res Mol Brain Res, 2002. 107(2): p. 
166-75.
79
95. Letavemier, E., et al., Targeting the calpain/calpastatin system as a new strategy 
to prevent cardiovascular remodeling in angiotensin 11-induced hypertension.
Circ Res, 2008. 102(6): p. 720-8.
96. Yoshikawa, Y., et al., Calpain inhibitor-1 protects the rat heart from ischemia- 
reperfusion injury: analysis by mechanical work and energetics. Am J Physiol 
Heart Circ Physiol, 2005. 288(4): p. H I690-8.
97. Maekawa, A., et al., Overexpression o f calpastatin by gene transfer prevents 
troponin I  degradation and ameliorates contractile dysfunction in rat hearts 
subjected to ischemia/reperfusion. J Mol Cell Cardiol, 2003. 35(10): p. 1277-84.
98. Arthur, J.S., et al., Disruption o f the murine calpain small subunit gene, Capn4: 
calpain is essential for embryonic development but not for cell growth and 
division. Mol Cell Biol, 2000. 20(12): p. 4474-81.
99. Mani, S.K., et al., Calpain inhibition preserves myocardial structure and function 
following myocardial infarction. Am J Physiol Heart Circ Physiol, 2009. 297(5): 
p. H I744-51.
100. Khalil, P.N., et al., Calpain inhibition reduces infarct size and improves global 
hemodynamics and left ventricular contractility in a porcine myocardial 
ischemia/reperfusion model. Eur J Pharmacol, 2005. 528(1-3): p. 124-31.
101. Saito, T., et al., Protective effects o f  calpain inhibitor for prolonged hypothermic 
cardiac preservation. Jpn J Thorac Cardiovasc Surg, 1999. 47(4): p. 145-52.
102. Aasum, E., et al., Age-dependent changes in metabolism, contractile function, and 
ischemic sensitivity in hearts from db/db mice. Diabetes, 2003. 52(2): p. 434-41.
103. Rees, D.A. and J.C. Alcolado, Animal models o f  diabetes mellitus. Diabet Med, 
2005. 22(4): p. 359-70.
104. Senador, D., et al., Cardiovascular and autonomic phenotype o f  db/db diabetic 
mice. Exp Physiol, 2009. 94(6): p. 648-58.
105. Bugger, H. and E.D. Abel, Rodent models o f diabetic cardiomyopathy. Dis Model 
Mech, 2009. 2(9-10): p. 454-66.
106. Semeniuk, L.M., A.J. Kryski, and D.L. Severson, Echocardiographic assessment 
o f  cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am J 
Physiol Heart Circ Physiol, 2002. 283(3): p. H976-82.
107. Aasum, E., et al., Cardiac function and metabolism in Type 2 diabetic mice after 
treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart 
Circ Physiol, 2002. 283(3): p. H949-57.
108.
8 0
Luttrell, I.P., et al., Erectile dysfunction in the type II diabetic db/db mouse: 
impaired venoocclusion with altered cavernosal vasoreactivity and matrix. Am J 
Physiol Heart Circ Physiol, 2008. 294(5): p. H2204-11.
109. John, B.T., et al., Global remodeling o f  the ventricular interstitium in idiopathic 
myocardial fibrosis and sudden cardiac death. Heart Rhythm, 2004. 1(2): p. 141- 
9.
110. Pauschinger, M., et al., Dilated cardiomyopathy is associated with significant 
changes in collagen type I/III ratio. Circulation, 1999. 99(21): p. 2750-6.
111. Takeda, N., et al., Cardiac fibroblasts are essential for the adaptive response o f  
the murine heart to pressure overload. J Clin Invest, 2010. 120(1): p. 254-65.
112. Zeisberg, E.M., et al., Endothelial-to-mesenchymal transition contributes to 
cardiac fibrosis. Nat Med, 2007.13(8): p. 952-61.
113. Desmouliere, A., et al., Transforming growth factor-beta 1 induces alpha-smooth 
muscle actin expression in granulation tissue myofibroblasts and in quiescent and 
growing cultured fibroblasts. J Cell Biol, 1993. 122(1): p. 103-11.
114. Hinz, B., et al., Alpha-smooth muscle actin is crucial for focal adhesion 
maturation in myofibroblasts. Mol Biol Cell, 2003. 14(6): p. 2508-19.
115. Subramanian, S.V., et al., Induction o f  vascular smooth muscle alpha-actin gene 
transcription in transforming growth factor beta 1-activated myofibroblasts 
mediated by dynamic interplay between the Pur repressor proteins and Spl/Smad 
coactivators. Mol Biol Cell. 2004. 15(10): p. 4532-43.
116. Ashizawa, N., et al., Osteopontin is produced by rat cardiac fibroblasts and 
mediates A(II)-induced DNA synthesis and collagen gel contraction. J Clin Invest, 
1996. 98(10): p. 2218-27.
117. Denhardt, D.T. and X. Guo, Osteopontin: a protein with diverse functions.
FASEB J, 1993. 7(15): p. 1475-82.
118. Denhardt, D.T., et al., Osteopontin as a means to cope with environmental insults: 
regulation o f  inflammation, tissue remodeling, and cell survival. J Clin Invest,
2001. 107(9): p. 1055-61.
119. Graf, K. and P. Stawowy, Osteopontin: a protective mediator o f  cardiac fibrosis? 
Hypertension, 2004. 44(6): p. 809-10.
120. Lenga, Y., et al., Osteopontin expression is required for myofibroblast 
differentiation. Circ Res, 2008. 102(3): p. 319-27.
81
121. Zahradka, P., Novel role fo r osteopontin in cardiac fibrosis. Circ Res, 2008. 
102(3): p. 270-2.
122. Chiappetta, N. and B. Gruber, The role o f mast cells in osteoporosis. Semin 
Arthritis Rheum, 2006. 36(1): p. 32-6.
123. Gruber, B.L., Mast cells: accessory cells which potentiate fibrosis. Int Rev 
Immunol, 1995. 12(2-4): p. 259-79.
124. Femex, M. and N.H. Stemby, Mast Cells and Coronary Heart Disease. 
Relationship between Number o f  Mast Cells in the Myocardium, Severity o f  
Coronary Atherosclerosis and Myocardial Infarction in an Autopsy Series o f 672 
Cases. Acta Pathol Microbiol Scand, 1964. 62: p. 525-38.
125. Gruber, B.L., et al., Human mast cells activate fibroblasts: tryptase is a fbrogenic  
factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast 
chemotaxis. J Immunol, 1997. 158(5): p. 2310-7.
126. Meng, H., et al., Mast cells induce T-cell adhesion to human fibroblasts by 
regulating intercellular adhesion molecule-1 and vascular cell adhesion 
molecule-1 expression. J Invest Dermatol, 1995. 105(6): p. 789-96.
127. Pauschinger, M., et al., Differential myocardial abundance o f  collagen type 1 and 
type III mRNA in dilated cardiomyopathy: effects o f  myocardial inflammation. 
Cardiovasc Res, 1998. 37(1): p. 123-9.
128. Weber, K.T., Fibrosis in hypertensive heart disease: focus on cardiac fibroblasts.
J Hypertens, 2004. 22(1): p. 47-50.
129. Bechtel, W., et al., Methylation determines fibroblast activation and fibrogenesis 
in the kidney. Nat Med, 2010. 16(5): p. 544-50.
130. Denhardt, D.T., et al., Osteopontin-induced modifications o f  cellular functions. 
Ann N Y Acad Sci, 1995. 760: p. 127-42.
131. Singh, K., et al., Myocardial osteopontin expression coincides with the 
development o f  heart failure. Hypertension, 1999. 33(2): p. 663-70.
132. Singh, M., et al., Osteopontin: a novel inflammatory mediator o f  cardiovascular 
disease. Front Biosci, 2007. 12: p. 214-21.
133. Singh, M., et al., Osteopontin: role in extracellular matrix deposition and 
myocardial remodelingpost-MI. J Mol Cell Cardiol, 2010. 48(3): p. 538-43.
82
134. Brower, G.L., et al., Cause and effect relationship between myocardial mast cell 
number and matrix metalloproteinase activity. Am J Physiol Heart Cire Physiol,
2002. 283(2): p. H518-25.
135. Ozbilgin, M.K. and S. Inan, The roles o f transforming growth factor type beta3 
(TGF-beta3) and mast cells in the pathogenesis o f scleroderma. Clin Rheumatol,
2003. 22(3): p. 189-95.
136. Bissonnette, E.Y., J.A. Enciso, and A.D. Befus, TGF-betal inhibits the release o f  
histamine and tumor necrosis factor-alpha from mast cells through an autocrine 
pathway. Am J Respir Cell Mol Biol, 1997. 16(3): p. 275-82.
137. Aceves, S.S., et al., Mast cells infiltrate the esophageal smooth muscle in patients 
with eosinophilic esophagitis, express TGF-betal, and increase esophageal 
smooth muscle contraction. J Allergy Clin Immunol, 2010. 126(6): p. 1198-204 
e4.
138. Akgul, A., et al., Role o f  mast cells and their mediators in failing myocardium 
under mechanical ventricular support. J Heart Lung Transplant, 2004. 23(6): p. 
709-15.
139. Ravinai, R.C., et al., Mast cells, TGF-betal and myofibroblasts expression in 
lupus nephritis outcome. Lupus, 2005. 14(10): p. 814-21.
140. Li, Y.Y., C.F. McTieman, and A.M. Feldman, Interplay o f  matrix 
metalloproteinases, tissue inhibitors o f  metalloproteinases and their regulators in 
cardiac matrix remodeling. Cardiovasc Res, 2000. 46(2): p. 214-24.
141. Aragno, M., et al., Oxidative stress triggers cardiac fibrosis in the heart o f  
diabetic rats. Endocrinology, 2008. 149(1): p. 380-8.
142. Aragno, M., et al., Oxidative stress-dependent impairment o f  cardiac-specific 
transcription factors in experimental diabetes. Endocrinology, 2006. 147(12): p. 
5967-74.
143. Rosen, P., X. Du, and D. Tschope, Role o f  oxygen derived radicals for vascular 
dysfunction in the diabetic heart: prevention by alpha-tocopherol? Mol Cell 
Biochem, 1998.188(1-2): p. 103-11.
144. Song, Y., et al., Diabetic Cardiomyopathy in OVE26 Mice Shows Mitochondrial 
ROS Production and Divergence Between In Vivo and In Vitro Contractility. Rev 
Diabet Stud, 2007. 4(3): p. 159-68.
145. Boudina, S. and E.D. Abel, Mitochondrial uncoupling: a key contributor to 
reduced cardiac efficiency in diabetes. Physiology (Bethesda), 2006. 21: p. 250-8.
146.
83
Boudina, S., et al., Reduced mitochondrial oxidative capacity and increased 
mitochondrial uncoupling impair myocardial energetics in obesity. Circulation, 
2005. 112(17): p. 2686-95.
147. Chen, M., et al., Calpain and mitochondria in ischemia/reperfusion injury. J Biol 
Chem, 2002. 277(32): p. 29181-6.
148. Duncan, J.G., Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim 
Biophys Acta, 2011. 1813(7): p. 1351-9.
149. Shen, X., et al., Protection o f  cardiac mitochondria by overexpression o f MnSOD 
reduces diabetic cardiomyopathy. Diabetes, 2006. 55(3): p. 798-805.
150. Du, X., K. Stocklauser-Farber, and P. Rosen, Generation o f reactive oxygen 
intermediates, activation o f NF-kappaB, and induction o f  apoptosis in human 
endothelial cells by glucose: role o f  nitric oxide synthase? Free Radie Biol Med, 
1999. 27(7-8): p. 752-63.
151. Nicoletti, A. and J.B. Michel, Cardiac fibrosis and inflammation: interaction with 
hemodynamic and hormonal factors. Cardiovasc Res, 1999. 41(3): p. 532-43.
152. Yokoyama, T., et al., Tumor necrosis factor-alpha provokes a hypertrophic 
growth response in adult cardiac myocytes. Circulation, 1997. 95(5): p. 1247-52.
153. Lee, F.Y., et al., mu-Calpain regulates receptor activator o f  NF-kappaB ligand 
(RANKL)-supported osteoclastogenesis via NF-kappaB activation in RA W 264.7 
cells. J Biol Chem, 2005. 280(33): p. 29929-36.
154. Yang, D., et al., Increased expression o f  calpain and elevated activity o f  
calcineurin in the myocardium ofpatients with congestive heart failure. Int J Mol 
Med, 2010. 26(1): p. 159-64.
A
